A Randomized, Open-label, Single-period, Parallel-group Study in Healthy Subjects to Determine the Effects of Dissolution Profile on the Pharmacokinetics (Via Both Venous and Peripheral Micro-samples) of Single Oral 300 mg Doses of Tafenoquine (SB-252263) Tablets + 30 mg Tafenoquine Stable Isotope Labelled (SIL) Solution
Latest Information Update: 25 Aug 2023
At a glance
- Drugs Tafenoquine (Primary) ; Tafenoquine (Primary)
- Indications Malaria
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 10 Sep 2018 Results published in the Antimicrobial Agents and Chemotherapy
- 09 Sep 2016 Status changed from active, no longer recruiting to completed.
- 20 Jul 2016 Status changed from recruiting to active, no longer recruiting.